Biotec Services International
Biotec Services International is recorded as a service provider in 10 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 10 of 10 trials · Latest update first
A phase III study to assess efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel 5%, applied once daily for 12 weeks in patients with acne vulgaris (GEDACNE-1)
Sponsor PPM Services S.A.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Sponsor Neurocrine Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement
Sponsor Elevar Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A long-term safety and efficacy study of N-Acetyl-GED-0507-34-LEVO gel 5%, in subjects with acne vulgaris (GEDACNE-LT)
Sponsor PPM Services S.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor
Sponsor Relay Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A phase III study to assess efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel 5%, applied once daily for 12 weeks in patients with acne vulgaris (GEDACNE-2)
Sponsor PPM Services S.A.
- Start (EU)
- Latest update
- Estimated end
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy.
Sponsor Syndax Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Sponsor Neurocrine Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose-Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease
Sponsor Agios Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants with Primary Hyperoxaluria Type 1 (PH1)
Sponsor Arbor Biotechnologies Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Biotec Services International?
The 2026-10-09 snapshot links Biotec Services International to 10 distinct CTIS trials. Recorded services include Medicinal product management, IMP Secondary Packaging & Labelling. IMP storage, distribution and destruction in UK. Final QP release in UK., IMP Secondary Packaging & Labelling. IMP storage, distribution and destruction in UK. Final QP release in UK, IP distribution and labeling, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Biotec Services International?
The most frequently recorded therapeutic areas are Dermatology, Endocrinology, Genetic and Congenital Disorders. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Biotec Services International conducted?
The linked trials record locations in 17 countries, including France, Spain, Italy, Poland, Belgium. These are trial locations, not confirmed office locations or countries where Biotec Services International delivered services.
What can this page tell me about Biotec Services International's trial experience?
Browse 10 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Biotec Services International. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Biotec Services International Limited